Gates Foundation commits US$2.5 billion to women’s health research
Bill & Melinda Gates Foundation Headquarters, Seattle, Washington
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
The investment, revealed yesterday at the foundation's Seattle headquarters, will support the advancement of more than 40 innovations across five critical areas that have historically received inadequate funding.
This significant financial pledge represents the foundation's largest investment in women's health research and development to date, marking a one-third increase compared to its investments over the previous five years.
The funding will target innovations particularly affecting women in low- and middle-income countries, with a focus on maternal, menstrual, gynaecological, and sexual health. According to Dr Anita Zaidi, president of the Gates Foundation's Gender Equality division, while this commitment is substantial, it still falls short of what is truly needed to address global women's health challenges.
"This investment builds upon our organisation's 25-year legacy of advancing maternal and child health and supporting women's empowerment globally," said Dr Zaidi in an interview following the announcement.
The foundation's commitment aligns with its ambitious long-term goals extending through 2045, which include helping to end preventable deaths of mothers and babies, ensuring future generations grow up without suffering from deadly infectious diseases, and lifting millions of people out of poverty and creating pathways to prosperity.
This latest funding commitment extends the foundation's decades of investments in global health innovations that benefit women and children. The Gates Foundation has previously invested in developing new contraceptives, portable diagnostic tools, and micronutrient supplements that have improved health outcomes worldwide.
The R&D commitment will complement the foundation's ongoing work supporting the scale-up and implementation of existing health solutions in communities across the globe.
Industry observers note that this announcement comes at a particularly crucial time, as some governmental funding for women's health research and international aid programmes has faced uncertainty in recent months.
The foundation expects to announce specific funding recipients and innovation projects in the coming weeks as it begins implementing this ambitious programme to transform women's health research and development.
Source:
Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation [Accessed August 5, 2025] https://www.gatesfoundation.org/ideas/media-center/press-releases/2025/08/womens-health-funding-commitmen
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...